Symposium
International
• Define research directions of novel agents and treatment.

The objectives of the Thirteenth International Kidney Cancer Symposium seeks to provide a forum for the exchange of ideas and information that will continue to frame directions for future research and treatment.

Objectives:
The objectives of the Thirteenth International Kidney Cancer Symposium are to:

- Evaluate the growing body of knowledge regarding clinical, molecular, genetic, and biologic characteristics of renal cell carcinoma
- Discuss the molecular genetics and biology of renal cancers and assess the effects of targeted therapy for this tumor
- Define research directions of novel agents and combinations and standard of care therapy for metastatic renal cell carcinoma
- Discuss options for operative minimally invasive management of localized and metastatic renal cell carcinoma
- Project future surgical and medical directions and research in non-metastatic and metastatic disease
- Define current agents in the treatment of advanced RCC
- Define current treatment guidelines for mRCC patients who develop progressive disease on VEGF therapy

Target Audience:
This meeting is directed to medical oncologists, urologists, and scientists involved in the clinical and research aspects of renal cell carcinoma.

Laurence Albiges, M.D.
The Lank Center for Genitourinary Oncology
dana-farber Cancer Institute
Boston, MA

Michael B. Atkins, M.D.
Georgetown University Medical Center and Lombardi Cancer Center
Washington, DC

Thomas D. Atwell, M.D.
Mayo Clinic
Rochester, MN

Georg A. Bjarnason, M.D.
Sunnybrook Health Science Centre
Toronto, Canada

Michael L. Blute, Jr., M.D.
University of Wisconsin School of Medicine and Public Health
Madison, WI

Michael L. Blute, Sr, M.D.
Massachusetts General Hospital
Harvard Medical School
Boston, MA

James Brugarolas, M.D., Ph.D.
University of Texas Southwestern Medical Center
Dallas, TX

Jonathan A. Coleman, M.D.
Memorial Sloan Kettering
New York, NY

Nicholas G. Cost, M.D.
University of Colorado School of Medicine
Denver, CO

Stephen H. Culp, M.D., Ph.D.
University of Virginia
Charlottesville, VA

Vijay Damarla, M.D., M.P.H.
Cleveland Clinic
Cleveland, OH

Fred Donskov, M.D.
Aarhus University Hospital
Aarhus, Denmark

Bernard J. Escudier, M.D.
Institut Gustave Roussy Villejuif, France

Andre P. Fay, M.D.
Dana Farber Cancer Institute
Boston, MA

Anthony Finelli, M.D.
Princess Margaret Hospital
Toronto, Canada

Jianjun Gao, M.D.
University of Texas
M.D. Anderson Cancer Center
Houston, TX

E. Jason Abel, M.D.
University of Wisconsin Hospital
Madison, WI

William P. Boo
Kidney Cancer Association
Chicago, IL

Toni K. Choueiri, M.D.
Dana-Farber Cancer Institute
Boston, MA

Brian I. Rini, M.D., Ph.D.
Cleveland Clinic Tausig Cancer Institute
Cleveland, OH

Nizar M. Tannir, M.D., FACP
University of Texas MD Anderson Cancer Center
Houston, TX

Laurence Albiges, M.D.
The Lank Center for Genitourinary Oncology
dana-farber Cancer Institute
Boston, MA

Jorge A. Garcia, M.D., FACP
Tausig Cancer Institute
Glickman Urological and Kidney Institute
Cleveland, OH

Naomi B. Haas, M.D.
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA

Ari Hakimi, M.D.
Memorial Sloan Kettering
New York, NY

Hans Joerg Hammers, M.D.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Thai Ho, M.D., Ph.D.
Mayo Clinic
Scottsdale, AZ

James Hsieh, M.D.
Memorial Sloan Kettering
New York, NY

Jose A. Karam, M.D.
University of Texas
M.D. Anderson Cancer Center
Houston, TX

Harriet Kluger, M.D.
Yale Department of Urology
New Haven, CT

Carolyn E. Konosky, MBA
Kidney Cancer Association
Chicago, IL

David Kwaitkowski, M.D.
University of Wisconsin Carbone Cancer Center
Madison, WI

Bradley C. Leibovich, M.D., FACS
Mayo Clinic
Rochester, MN

Gabriel G. Malouf, M.D.
University of Wisconsin
Madison, WI

Joshua M. Lang, M.D., MS
Brigham and Women’s Hospital
Boston, MA

Sumanta Pal, M.D.
City of Hope Comprehensive Cancer Center
Duarte, CA

Drew Pardoll, M.D., Ph.D.
Johns Hopkins School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Roberto Pli, M.D.
Roswell Park Cancer Institute
Buffalo, NY

Elizabeth Pliimack, M.D.
Fox Chase Cancer Center
Philadelphia, PA

Joel M. Prince, B.S.
University of Wisconsin School of Medicine and Public Health
Madison, WI

Sarah Psutka, M.D.
Mayo Clinic
Rochester, MN

Mark Purdue, M.D.
Ontario Institute of Cancer Research
Toronto, Canada

David I. Quinn, M.D., Ph.D., MBBS, FRACP
USC Kenneth Norris Cancer Center
Los Angeles, CA

Brian Shuch, M.D.
Yale Department of Urology
New Haven, CT

Philippe E. Spieks, M.D.
Moffitt Cancer Center
Tampa, FL

Sumane L. Topolian, M.D.
Johns Hopkins School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Andrew G. Winer, M.D.
Memorial Sloan-Kettering Cancer Center
New York, NY

Christopher G. Wood, M.D., FACS
University of Texas
M.D. Anderson Cancer Center
Houston, TX

XiFeng Wu, M.D.
University of Texas
M.D. Anderson Cancer Center
Houston, TX

R. Houston Thompson, M.D.
Mayo Clinic
Rochester, MN

Laura Wood, R.N., MSN, OCN
Cleveland Clinic
Cleveland, OH

Nancy Moldawer, R.N., MSN
Cedars-Sinai Medical Center
Los Angeles, CA

Thirteenth International Kidney Cancer Symposium

October 24-25, 2014
Radisson Blu Aqua Hotel
Chicago, Illinois 60601 USA

Overview:
Bringing together key individuals and representatives from leading laboratories and centers working with renal cell carcinoma, the Thirteenth International Kidney Cancer Symposium seeks to provide a forum for the exchange of ideas and information that will continue to frame directions for future research and treatment.

THE KIDNEY CANCER SYMPOSIUM
THIRTEENTH INTERNATIONAL KIDNEY CANCER SYMPOSIUM–2014

Scientific Program Committee

Faculty/Affiliation
SCIENTIFIC PROGRAM
Thirteenth International Kidney Cancer Symposium
Chicago — October 24-25, 2014

Friday, October 24, 2014

7:00-8:00 am  Breakfast and Registration

8:00-8:02 am  KCA Welcome
Kidney Cancer Association
Carolyn E. Konosky, MBA

8:02-8:05 am  Welcome Speaker
Toni K. Choueiri, M.D.

Epidemiology and Management of Localized RCC
Moderator: E. Jason Abel, M.D.

8:05-8:20 am  Projecting Individual Probability for Developing Renal Cell Cancer
XiFeng Wu, M.D.

8:20-8:30 am  Epidemiology and Molecular Markers in RCC
Mark Purdue, M.D.

8:30-8:40 am  The Benefits and Limitations of Biopsy for Risk Stratification in RCC
E. Jason Abel, M.D.

8:40-8:50 am  Management of Kidney Cancer in Young Patients
Brian Shuch, M.D.

8:50-9:00 am  Hereditary Syndromes in Kidney Cancer; Beyond VHL
Nicholas G. Cost, M.D.

9:00-9:10 am  Debate: Partial Nephrectomy for t1b/t2a RCC
Tim Masterson, M.D.

9:10-9:20 am  Debate: Radical Nephrectomy for t1b/t2a RCC
Vitaly Margulis, M.D.

9:20-9:25 am  AUA and NCCN Surveillance Guidelines for RCC: Do They Effectively Capture Recurrences Following Nephrectomy?
R. Houston Thompson, M.D.

9:25-9:30 am  Patient and Tumor Characteristics Predict Indeterminate Renal Mass Biopsy Findings
Joel M. Prince, B.S.

9:30-9:42 am  Break

Locally-Advanced RCC
Moderator: R. Houston Thompson, M.D.

9:42-9:52 am  Quality Indicators in RCC Care
Anthony Finelli, M.D.

9:52-10:02 am  Neoadjuvant Targeted Therapy
Jose A. Karam, M.D.

10:02-10:12 am  Ablation of Larger and Recurrent Tumors
Thomas D. Atwell, M.D.

10:12-10:22 am  Pros and Cons of Node Dissection for Local Advanced RCC
Jonathan A. Coleman, M.D.

10:22-10:32 am  Latest on IVC Tumor Thrombus
Sarah Psutka, M.D.

10:32-10:42 am  Cytoreductive Nephrectomy
Steven Culp, M.D.

10:42-10:47 am  Recurrence After Surgery in Non-Metastatic RCC with Thrombus; Risk Factors from a Contemporary Multicenter Analysis
Michael L. Blute, Jr. M.D.

10:47-11:07 am  Summary/Case Presentations
Michael L. Blute, Sr., M.D.

11:07-11:20 am  Break

11:20-11:50 am  Novick Lecture:
Bradley C. Leibovich, M.D., FACS

11:50-1:05 pm  Lunch and Poster Display

Non-Clear Cell RCC
Moderator: Nizar M. Tannir, M.D., FACP

1:05-1:15 pm  Chromophobe RCC
James Hsieh, M.D.

1:15-1:25 pm  Papillary RCC
Laurence Albiges, M.D., Ph.D.

1:25-1:35 pm  XP11.2 RCC
Gabriel Malouf, M.D.

1:35-1:45 pm  Renal Medullary Carcinoma
Jianjun Gao, M.D.

1:45-1:55 pm  Sarcomatoid/Biology/Clinical
Abraham Hakimi, M.D.

1:55-2:05 pm  ESPN, ASPEN and Beyond
Toni K. Choueiri, M.D.

2:05-2:40 pm  Break
**Immunotherapy and/or TKIs as the Future of Front Line mRCC Therapy**  
*Moderator: Brian I. Rini, M.D.*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:40-3:20 pm</td>
<td>The Biology of Checkpoint Inhibition</td>
</tr>
<tr>
<td></td>
<td>Drew Pardoll, M.D.</td>
</tr>
<tr>
<td>3:20-3:30 pm</td>
<td>Immunotherapy is the Optimal Front-Line mRCC Treatment</td>
</tr>
<tr>
<td></td>
<td>Michael B. Atkins, M.D.</td>
</tr>
<tr>
<td>3:30-3:40 pm</td>
<td>TKIs are the Optimal Front-Line mRCC Treatment</td>
</tr>
<tr>
<td></td>
<td>M. Dror Michaelson, M.D., Ph.D.</td>
</tr>
<tr>
<td>3:40-3:50 pm</td>
<td>Combinations of Immunotherapy and TKIs are the Optimal Front-Line mRCC Therapy</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Plimack, M.D.</td>
</tr>
<tr>
<td>3:50-4:10 pm</td>
<td>Biomarkers on Checkpoint Inhibition</td>
</tr>
<tr>
<td></td>
<td>Suzanne L. Topalian, M.D.</td>
</tr>
<tr>
<td>4:10-4:15 pm</td>
<td>Immune Correlates and Long-Term Follow-up of a Phase Ia Study of MPDL-3280A, An Engineered PD-L1 Antibody, in Patients with Metastatic Renal Cell Carcinoma (mRCC)</td>
</tr>
<tr>
<td></td>
<td>David F. McDermott, M.D.</td>
</tr>
<tr>
<td>4:15-4:20 pm</td>
<td>Immune Cell Repertoire in Patients with Metastatic Renal Cell Carcinoma: Data From Prospective Clinical Trial</td>
</tr>
<tr>
<td></td>
<td>Vijay Damarla, M.D., M.P.H.</td>
</tr>
<tr>
<td>4:20-4:25 pm</td>
<td>Abstract- Phase 1 Study of Nivolumab in Combination with Ipilimumab (IPI) in Metastatic Renal Cell Carcinoma (mRCC)</td>
</tr>
<tr>
<td></td>
<td>Hans Joerg Hammers, M.D.</td>
</tr>
<tr>
<td>4:25 pm</td>
<td>Adjourn</td>
</tr>
<tr>
<td>6:00-8:00 pm</td>
<td>Evening Reception at the International Museum of Surgical Science. Departing from the South Exit outside the Atlantic Ballroom.</td>
</tr>
</tbody>
</table>

**Saturday, October 25, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00 am</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8:00-8:05 am</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td>Laura Wood, R.N., MSN, OCN</td>
</tr>
</tbody>
</table>

**Balancing Dose Delivery and Toxicity of Systemic Therapy**  
*Moderator: Laura Wood, R.N., MSN, OCN*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:05-8:30 am</td>
<td>Toxicity as a Biomarker</td>
</tr>
<tr>
<td></td>
<td>Fred Donskov, M.D.</td>
</tr>
<tr>
<td>8:30-8:45 am</td>
<td>Dose Reduction or Treatment Interruption: Pro Dose Reduction</td>
</tr>
<tr>
<td></td>
<td>David I. Quinn, M.D., Ph.D., MBBS, FRACP</td>
</tr>
<tr>
<td>8:45-9:00 am</td>
<td>Dose Reduction or Treatment Interruption: Pro Treatment Interruption/Schedule Alteration</td>
</tr>
<tr>
<td></td>
<td>Georg Bjarnason, M.D.</td>
</tr>
<tr>
<td>9:00-9:10 am</td>
<td>Updates in Toxicity Management &amp; Education Resources</td>
</tr>
<tr>
<td></td>
<td>Nancy Moldawer, R.N., MSN</td>
</tr>
<tr>
<td>9:10-9:15 am</td>
<td>Bacteriomic Profiling Reveals Potential Etiology for Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (VEGF-TKI)-Related Diarrhea in Patients with Metastatic Renal Cell Carcinoma</td>
</tr>
<tr>
<td></td>
<td>Sumanta Pal, M.D.</td>
</tr>
<tr>
<td>9:15-9:20 am</td>
<td>Risk Factors and a Model to Predict Toxicity-related Treatment Discontinuation in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy: Results from the International Metastatic RCC Database Consortium (IMDC)</td>
</tr>
<tr>
<td></td>
<td>Toni K. Choueiri, M.D.</td>
</tr>
<tr>
<td>9:20-9:50 am</td>
<td>Break</td>
</tr>
</tbody>
</table>
New Biologic Insights
Moderators: Toni K. Choueiri, M.D., Roberto Pili, M.D.

9:50-10:10 am  Biology-Based Classification of RCC
James Brugarolas, M.D., Ph.D.

10:10-10:30 am  Chromatin and Epigenetics
Thai Ho, M.D., Ph.D.

10:30-10:45 am  MET Pathway as a Target in RCC
Harriet Kluger, M.D.

10:45-11:00 am  mTOR Biology
David Kwiatkowski, M.D.

11:00-11:15 am  CTC’s in RCC
Joshua Lang, M.D., M.S.

11:15-11:50 am  Schonfeld Lecture
Bernard J. Escudier, M.D.

11:50-1:00 pm  Lunch

1:00-2:05 pm  Interactive Panel with Medical Oncologists and Surgeons (Case Based)
Moderator: Christopher G. Wood, M.D., FACS
Panelist: Naomi B. Haas, M.D., Philippe E. Spiess, M.D., Jorge A. Garcia, M.D., FACP, R. Houston Thompson, M.D.

Invited Abstracts
Moderators: E. Jason Abel, M.D., Nizar M. Tannir, M.D., FACP

2:05-2:10 pm  Tumor Purity and Immune Cell Infiltration as a Prognostic Risk Predictor for Clear Cell Renal Cell Carcinoma
Andrew G. Winer, M.D.

2:10-2:15 pm  Differential Expression of MET Between Primary and Metastatic Sites in Clear Cell Renal Cell Carcinomas (CCRCCs)
Laurence Albiges, M.D., Ph.D.

2:15-2:20 pm  Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma (mRCC)
Andre P. Fay, M.D.

2:20-2:25 pm  Cost Analysis of an Initial Observation Approach in Metastatic Renal Cell Carcinoma from a Prospective Study
Hiral D. Parekh, M.D.

2:25 pm  Adjourn